These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 37051591)
1. Screening Yang T; Chi Z; Liu G; Hong X; Cao S; Cheng K; Zhang Y Front Genet; 2023; 14():1107625. PubMed ID: 37051591 [No Abstract] [Full Text] [Related]
2. ANLN Serves as an Oncogene in Bladder Urothelial Carcinoma via Activating JNK Signaling Pathway. Chen S; Gao Y; Chen F; Wang TB Urol Int; 2023; 107(3):310-320. PubMed ID: 35504258 [TBL] [Abstract][Full Text] [Related]
3. Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. Zeng S; Yu X; Ma C; Song R; Zhang Z; Zi X; Chen X; Wang Y; Yu Y; Zhao J; Wei R; Sun Y; Xu C Sci Rep; 2017 Jun; 7(1):3151. PubMed ID: 28600503 [TBL] [Abstract][Full Text] [Related]
4. A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival. Chen Z; Liu G; Hossain A; Danilova IG; Bolkov MA; Liu G; Tuzankina IA; Tan W Hereditas; 2019; 156():24. PubMed ID: 31333338 [TBL] [Abstract][Full Text] [Related]
5. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome. Li C; Wan Z; Deng Q; Li Z; Wang Y Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960 [TBL] [Abstract][Full Text] [Related]
6. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer. Wang Z; Tu L; Chen M; Tong S BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144 [TBL] [Abstract][Full Text] [Related]
7. Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data. Xu Y; Wu G; Li J; Li J; Ruan N; Ma L; Han X; Wei Y; Li L; Zhang H; Chen Y; Xia Q Biomed Res Int; 2020; 2020():8283401. PubMed ID: 32047816 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of the ASPM gene is associated with aggressiveness and poor outcome in bladder cancer. Xu Z; Zhang Q; Luh F; Jin B; Liu X Oncol Lett; 2019 Feb; 17(2):1865-1876. PubMed ID: 30675249 [TBL] [Abstract][Full Text] [Related]
9. The Prognostic Hub Gene POLE2 Promotes BLCA Cell Growth via the PI3K/AKT Signaling Pathway. Jiang D; Zhang H; Yin B; He M; Lu X; He C Comb Chem High Throughput Screen; 2024; 27(13):1984-1998. PubMed ID: 38963027 [TBL] [Abstract][Full Text] [Related]
10. Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis. Wang Y; Chen L; Ju L; Qian K; Liu X; Wang X; Xiao Y Front Oncol; 2019; 9():1030. PubMed ID: 31681575 [TBL] [Abstract][Full Text] [Related]
11. Identification of Hub Genes Associated with Progression and Prognosis of Bladder Cancer by Integrated Bioinformatics Analysis. Jiang S; Ma J; Wei S; Ren P; Liu J; Zhou Y; Liu D; Zhang X Arch Esp Urol; 2022 Nov; 75(9):779-790. PubMed ID: 36472061 [TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of the Prognostic Stemness Biomarkers in Bladder Cancer Bone Metastasis. Kang Y; Zhu X; Wang X; Liao S; Jin M; Zhang L; Wu X; Zhao T; Zhang J; Lv J; Zhu D Front Oncol; 2021; 11():641184. PubMed ID: 33816287 [TBL] [Abstract][Full Text] [Related]
13. Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis. Cai D; Zhou Z; Wei G; Wu P; Kong G Front Genet; 2022; 13():952369. PubMed ID: 36118856 [No Abstract] [Full Text] [Related]
14. Comprehensive Investigation of Genes Associated with Cell Cycle Pathways for Prognosis and Immunotherapy in Bladder Urothelial Carcinoma. Mi Y; Wang X J Environ Pathol Toxicol Oncol; 2022; 41(3):1-12. PubMed ID: 35993952 [TBL] [Abstract][Full Text] [Related]
15. Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes. Zhao H; Chen Z; Fang Y; Su M; Xu Y; Wang Z; Gyamfi MA; Zhao J J Immunol Res; 2022; 2022():1793005. PubMed ID: 35450397 [TBL] [Abstract][Full Text] [Related]
16. Identification of Immune-Related Subtypes and Construction of a Novel Prognostic Model for Bladder Urothelial Cancer. Zhang J; Huang C; Yang R; Wang X; Fang B; Mi J; Yuan H; Mo Z; Sun Y Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421685 [TBL] [Abstract][Full Text] [Related]
17. Identification of Potential Biomarkers for Progression and Prognosis of Bladder Cancer by Comprehensive Bioinformatics Analysis. Tan Z; Fu S; Feng R; Huang Y; Li N; Wang H; Wang J J Oncol; 2022; 2022():1802706. PubMed ID: 35498536 [No Abstract] [Full Text] [Related]
18. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606 [TBL] [Abstract][Full Text] [Related]
19. Clinical implication and immunological landscape analyses of ANLN in pan-cancer: A new target for cancer research. Zhang L; Wei Y; He Y; Wang X; Huang Z; Sun L; Chen J; Zhu Q; Zhou X Cancer Med; 2023 Feb; 12(4):4907-4920. PubMed ID: 36030492 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of PTCD1 in Bladder Urothelial Carcinoma Predicts Poor Prognosis and Levels of Immune Infiltration. Zhou Z; Zhou Y; Zhou X; Huang Y; Cui Y; Zhang Y J Oncol; 2022; 2022():1146186. PubMed ID: 35799606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]